Alqarni Afnan A, Alamoudi Aliaa A, Allam Rasha M, Ajabnoor Ghada M, Harakeh Steve M, Al-Abd Ahmed M
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia; Regenerative medicine unit, King Fahd Medical Research Centre, Jeddah 21589, Saudi Arabia.
Biomed Pharmacother. 2022 May;149:112835. doi: 10.1016/j.biopha.2022.112835. Epub 2022 Mar 21.
Breast cancer remains a leading cause of female mortality worldwide. Therefore, novel complementary treatments have been sought. Recently, there has been a growing interest in investigating the possible complementary effects of polyphenolic compounds against various malignancies. In the present study, using MCF-7 and MDA-MB-231 human breast adenocarcinoma cells, the anticancer efficacy of a polyphenolic mixture (PFM) was investigated. PFM is composed of curcumin, resveratrol, epigallocatechin gallate, and quercetin. PFM treatment led to a dose-dependent inhibition of cell proliferation, with IC values of 25.9 ± 3 µg/ml and 29.4 ± 0.9 µg/ml for MCF-7 and MDA-MB-231 cells, respectively. In addition, PFM induced apoptosis in MDA-MB-231 cells and cell cycle arrest at the S phase in MCF-7 cells. Using RT-qPCR, PFM treatment was observed to result in significant downregulation of the oncogenic miR-155 (P < 0.05), as well as significant downregulation of the rate-limiting glycolytic enzyme, hexokinase 2 (HK2) (P < 0.05), while upregulating the expression of the zinc finger E-box binding homeobox 2 gene (P < 0.01). PFM was also found to exert an anti-migration effect in breast cancer cells using the wound healing assay, as well as significantly (P < 0.05) increasing the median survival of Ehrlich ascites carcinoma (EAC) tumor-bearing mice. These results suggest that PFM possesses potential antitumor effects against breast cancer. A possible mechanism of action could be due to PFM's effect in modulating the expression of the glycolytic enzyme HK2 through suppression of miR-155 in MCF-7 cells. Combining polyphenolic compounds that interact with one another could result in synergistic effects that potentially target various tumour hallmarks.
乳腺癌仍然是全球女性死亡的主要原因。因此,人们一直在寻找新的辅助治疗方法。最近,研究多酚类化合物对各种恶性肿瘤可能的辅助作用的兴趣日益浓厚。在本研究中,使用MCF-7和MDA-MB-231人乳腺腺癌细胞,研究了一种多酚混合物(PFM)的抗癌效果。PFM由姜黄素、白藜芦醇、表没食子儿茶素没食子酸酯和槲皮素组成。PFM处理导致细胞增殖呈剂量依赖性抑制,MCF-7和MDA-MB-231细胞的IC值分别为25.9±3μg/ml和29.4±0.9μg/ml。此外,PFM诱导MDA-MB-231细胞凋亡,并使MCF-7细胞在S期发生细胞周期阻滞。使用RT-qPCR观察到,PFM处理导致致癌性miR-155显著下调(P<0.05),以及限速糖酵解酶己糖激酶2(HK2)显著下调(P<0.05),同时上调锌指E盒结合同源盒2基因的表达(P<0.01)。使用伤口愈合试验还发现,PFM对乳腺癌细胞具有抗迁移作用,并且显著(P<0.05)提高了荷艾氏腹水癌(EAC)肿瘤小鼠的中位生存期。这些结果表明,PFM对乳腺癌具有潜在的抗肿瘤作用。一种可能的作用机制可能是由于PFM通过抑制MCF-7细胞中的miR-155来调节糖酵解酶HK2的表达。相互作用的多酚类化合物组合可能会产生协同效应,潜在地针对各种肿瘤特征。